瑞康医药(002589) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥2,024,529,328.71, a decrease of 0.03% compared to the same period last year[2] - The net profit attributable to shareholders for Q3 2024 was ¥7,780,988.85, an increase of 167.97% year-on-year[2] - The net profit after deducting non-recurring gains and losses for the year-to-date was ¥38,806,313.59, up 101.90% compared to the previous year[2] - Basic earnings per share for Q3 2024 were ¥0.0052, reflecting a year-on-year increase of 168.42%[2] - Total operating revenue for Q3 2024 was CNY 6,056,194,532.51, a decrease of 0.8% compared to CNY 6,105,062,530.67 in Q3 2023[14] - Net profit for Q3 2024 was CNY 52,249,021.31, an increase of 87.7% compared to CNY 27,832,019.60 in Q3 2023[15] - Earnings per share for Q3 2024 was CNY 0.0258, up from CNY 0.0128 in the same period last year[15] - The total comprehensive income for Q3 2024 was CNY 52,249,021.31, compared to CNY 27,832,019.60 in Q3 2023[15] Assets and Liabilities - Total assets at the end of Q3 2024 were ¥16,418,850,033.63, a decrease of 1.74% from the end of the previous year[2] - Total current assets amounted to CNY 11,566,826,407.05, slightly up from CNY 11,539,092,710.53 at the beginning of the period[12] - Total liabilities decreased to CNY 10,713,579,497.11 from CNY 11,072,329,037.39 year-over-year[14] - The company's total equity attributable to shareholders increased by 1.07% to ¥5,506,126,278.20 compared to the end of the previous year[2] - The company's equity attributable to shareholders increased to CNY 5,506,126,278.20 from CNY 5,447,793,713.64 in the previous year[14] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥8,276,900.24, a significant decrease of 96.56% compared to the previous year[2] - Cash received from operating activities fell by 74.24% to CNY 12,429.76 million, down from CNY 48,245.71 million year-on-year[8] - Cash inflow from operating activities was CNY 6,652,723,709.54, compared to CNY 7,277,559,775.64 in Q3 2023[17] - The net cash flow from operating activities for Q3 2024 was CNY 11,429,670.97, a significant decrease from CNY 332,495,045.47 in Q3 2023[17] - The total cash inflow from investment activities was CNY 468,658,637.64, down from CNY 1,041,094,767.33 in the same period last year[17] - The net cash flow from financing activities was negative at CNY -136,866,455.77, compared to CNY -827,867,599.15 in Q3 2023[18] - The total cash outflow from financing activities was CNY 15,110,791,313.19, a decrease from CNY 16,356,808,464.38 in the previous year[18] Investment and Income - The company reported a 144.66% increase in notes receivable, reaching ¥53,101.34 million, due to an increase in accepted bills[5] - The company experienced a 93.03% decrease in investment income, totaling ¥2,901.49 million, attributed to the divestiture of a subsidiary[6] - The company reported a significant increase in investment income to CNY 29,014,904.55 from CNY 416,512,053.59 in the previous year[14] - Cash received from investment income increased significantly by 974.79% to CNY 17,438.12 million from CNY 863.16 million in the previous year[8] Expenses and Costs - Total operating costs decreased to CNY 5,997,705,441.86, down 3.4% from CNY 6,210,217,250.06 in the previous year[14] - Research and development expenses for Q3 2024 were CNY 7,566,022.65, down from CNY 10,177,007.27 in Q3 2023[14] - The cash paid for employee compensation was CNY 215,025,230.78, slightly up from CNY 214,867,599.93 in the previous year[17] Other Financial Metrics - The company recorded a credit impairment loss of ¥4,274.15 million, a significant increase of 431.23% due to higher provisions for receivables[7] - Cash flow from tax refunds decreased by 99.90% to CNY 2.08 million compared to CNY 2,182.33 million in the same period last year[8] - Cash received from tax refunds was CNY 20,780.92, compared to CNY 21,823,281.06 in Q3 2023[17] - The number of common shareholders at the end of the reporting period was 77,973[9]